



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

APR 24 1998

Mr. David Wagner Director, Quality Assurance Imex Medical Systems Inc. 6355 Joyce Dr. Golden CO 80403 Re: K973556

IMEXLAB 9000 Diagnostic Ultrasound Device

Dated: January 13, 1998 Received: January 26, 1998

Regulatory Class: II

21 CFR 892.1550/Procode: 90 IYN

Dear Mr. Wagner:

We have reviewed your section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug and Cosmetic Act. You may, therefore, market the device, subject to the general controls provisions Act (Act). The general controls provisions of the Act include requirements for registration, listing of devices, good manufacturing practices, labeling, and prohibitions against misbranding and adulteration.

This determination of substantial equivalence applies to the following transducers intended for use with the IMEXLAB 9000 as described in your premarket notification:

Transducer Model Numbers

5 MHz CW

8 MHz CW

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval) it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus permits your device to proceed to market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4591. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or at (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".

If you have any questions regarding the content of this letter, please contact Maureen Butler at (301) 594-1212.

Sincerely yours,

Lillian Yin, Ph.D.

Director, Division of Reproductive, Abdominal, Ear, Nose and Throat, and Radiological Devices Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

510(k) Number (if knowr	n): <u>#K973556</u>	
Device Name: <u>IMEXLAB</u>	9000	
Indications for Use:		
detection of peripheral va	ascular diseases. ascular laboratory, clinic o	stem designed to assist in the
It is not indicated for use	near non-intact skin or the	e eyes.
It is not intended for hom	ne use.	
. •	,	
(PLEASE DO NOT WRIT NEEDED)	'E BELOW THIS LINE - C	ONTINUE ON ANOTHER PAGE I
Concurren	ce of CDRH, Office of Dev	vice Evaluation (ODE)
	(Division Sign-Off) Division of Reproductive, Abdo and Radiological Devices 510(k) Number	minal, ENT,
Prescription Use (per 21 CFR 801.109)	OR	Over-The-Counter Use
		(Optional Format 1-2-96)

Diagnostic Ultrasound Indications for Use Form

Fill out one form for each ultrasound system and each transducer.

Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:

Clinical Application		т —	·	,	·	Mode	of Operation				
	A	В	М	PWD	CWD	Color Doppler	Amplitude Doppler	Color Velocity Imaging	Combined (specify)	Other (specify	
Ophthalmic		<u> </u>									
Fetal											
Abdominal						·					
Intraoperative (specify)											
Intraoperative Neurological											
Pediatric											
Small Organ (specify)											
Neonatal Cephalic											
Adult Cephalic										'	
Cardiac											
Transesophageal											
Transrectal											
Transvaginal											
Transurethral			4	-							
Intravascular											
Peripheral Vascular											
Laparoscopic											
Musculo-skeletal Conventional											
Musculo-skeletal Superficial										-	
Other (specify)											
N= new indication; P= p	revious	sly cle	eared	by FD	A; E=	added u	nder Appen	ndix E	<u> </u>		
Additional Comments:	REF	: :	<u> </u>	73	<u>55</u>	6		EXLAB	9000	<u></u>	
							-				
								the second			
(PLEA	SE DO NO	TWRITE	BELOW	THIS UN	E-CONT	NUE ON ANOT	HER PAGE IF NE	EDED)	<u> </u>	۱۷d	
	CONCU	irence	OT CD	KH, Off	ice of D	1// 1	ration (ODE)		:: ===================================	10 D	
					3	ivision Si	Ca N	Jami	دت	CDRH/ODE/DMC	
		(Division Sign-Off) Division of Reproductive, Abdominal, ENT,								100	
rescription Use (Per 21 (rescription Use (Per 21 CFR 801.109)			an	and Radiological Devices						
,		, 3	-,			O(k) Numb		250	26	0	

SK-31

Diagnostic Ultrasound Indications for Use Form

Fill out one form for each ultrasound system and each transducer.

Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:

Clinical Application		·	,	_	,	Mode	of Operation		I	<u> </u>
	Α	В	М	PWD	CWD	Color Doppler	Amplitude Doppler	Color Velocity Imaging	Combined (specify)	Other (specify)
Ophthalmic			<u></u>							
Fetal			<u> </u>							
Abdominal				<u> </u>	<u> </u>					
Intraoperative (specify)			ļ	<u> </u>						
Intraoperative Neurological			<u> </u>							
Pediatric			<u> </u>							
Small Organ (specify)				<u> </u>						
Neonatal Cephalic			<u> </u>							
Adult Cephalic										
Cardiac										
Transesophageal					<u> </u>					ļ
Transrectal			ļ		<u> </u>					
Transvaginal										
Transurethral										
Intravascular										
Peripheral Vascular										
Laparoscopic										
Musculo-skeletal Conventional								44,		
Musculo-skeletal Superficial										
Other (specify)										
N= new indication; P= p Additional Comments:	ize	F	cleare	·····································	73	== added 55%	5	DIEST	٠ ،	
					·			TRAN	2 Dr CEC	
								est t	دن	25.
								A.c.		
——————————————————————————————————————	ACC DO	NOT	OITC OF	OMTU	LINE CO	MITIAN IS ON A	NOTHER PAGE IF	NEEDED!	5	- 1
(PLE							valuation (OD			
Prescription Use (Per 21	CFR	801.	109)			Division	orogicai Dev	Lynn etive, Abdo	minal, ENT,	- د